文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

中度低温与正常体温对接受静脉-动脉体外膜氧合的心源性休克患者30天死亡率的影响:一项随机临床试验

Effect of Moderate Hypothermia vs Normothermia on 30-Day Mortality in Patients With Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01
一句话结论在接受静脉-动脉体外膜氧合的心源性休克患者中,早期24小时中度低温(33-34°C)与严格正常体温(36-37°C)相比未显著改善30天生存率,但95%CI宽且包括可能重要的效应量,作者认为结果不确定。

这项在法国20个心脏休克中心ICU进行的随机临床试验,纳入374例因心源性休克接受静脉-动脉ECMO且插管<6小时的患者,随机分为早期中度低温(33-34°C,24小时,n=168)或严格正常体温(36-37°C,n=166)。主要终点30天死亡率两组无显著差异:低温组42% vs 正常体温组51%(校正OR 0.71,95%CI 0.45-1.13,P=0.15;风险差-8.3%,95%CI -16.3%至-0.3%)。30天死亡、心脏移植、升级至左心室辅助装置或卒中的复合终点校正OR 0.61(95%CI 0.39-0.96,P=0.03),风险差-11.5%(95%CI -23.2%至0.2%)。31个次要终点中30个无结论性。作者结论为早期中度低温未显著增加生存率,但95%CI宽且包括可能重要的效应量,结果应视为不确定。

要点

  • 在因心源性休克接受静脉-动脉ECMO且插管<6小时的患者中,早期24小时中度低温(33-34°C)与严格正常体温(36-37°C)相比,30天死亡率42% vs 51%,校正OR 0.71(95%CI 0.45-1.13,P=0.15),未达统计学显著。
  • 30天死亡、心脏移植、升级至左心室辅助装置或卒中的复合终点:低温组校正OR 0.61(95%CI 0.39-0.96,P=0.03),风险差-11.5%(95%CI -23.2%至0.2%)。
  • 31个次要终点中30个无结论性。
  • 中度或严重出血发生率低温组41% vs 正常体温组42%;感染发生率两组均为52%;菌血症低温组20% vs 正常体温组30%。
  • 作者认为,由于95%CI宽且包括可能重要的效应量,该试验结果应视为不确定。

适用人群与场景

  • 因心源性休克接受静脉-动脉ECMO且已气管插管、接受ECMO时间<6小时的患者。
  • 在法国20个心脏休克中心的ICU开展;纳入标准为心源性休克接受静脉-动脉ECMO且插管<6小时。

处置流程与药物剂量

  • 早期中度低温组:目标温度33-34°C,持续24小时(n=168)。
  • 严格正常体温组:目标温度36-37°C(n=166)。

研究设计与关键结果

  • 随机临床试验,在法国20个心脏休克中心ICU进行,2016年10月至2019年7月纳入;786例符合条件,374例随机,334例完成试验并纳入主要分析(平均年龄58岁[SD 12],24%女性)。
  • 主要终点30天死亡率:中度低温组42% vs 正常体温组51%,校正OR 0.71(95%CI 0.45-1.13,P=0.15);风险差-8.3%(95%CI -16.3%至-0.3%)。
  • 30天死亡、心脏移植、升级至左心室辅助装置或卒中的复合终点:校正OR 0.61(95%CI 0.39-0.96,P=0.03),风险差-11.5%(95%CI -23.2%至0.2%)。
  • 31个次要终点中30个无结论性。
  • 中度或严重出血发生率:中度低温组41% vs 正常体温组42%;感染发生率两组均为52%;菌血症发生率:中度低温组20% vs 正常体温组30%。

证据类型、等级与局限

  • 证据类型:随机临床试验(RCT),试验注册号ClinicalTrials.gov NCT02754193。
  • 作者结论:早期中度低温24小时与正常体温相比未显著增加生存率;因95%CI宽且包括可能重要的效应量,结果应视为不确定。
  • 局限:原文报告95%CI宽且包括可能重要的效应量,结果应视为不确定;31个次要终点中30个无结论性。

对床旁实践的改变

  • 对于因心源性休克接受静脉-动脉ECMO且插管<6小时的患者,早期24小时中度低温(33-34°C)与严格正常体温(36-37°C)相比,30天死亡率无显著差异。
  • 作者认为,由于95%CI宽且包括可能重要的效应量,该试验结果应视为不确定。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The optimal approach to the use of venoarterial extracorporeal membrane oxygenation (ECMO) during cardiogenic shock is uncertain.

OBJECTIVE: To determine whether early use of moderate hypothermia (33-34 °C) compared with strict normothermia (36-37 °C) improves mortality in patients with cardiogenic shock receiving venoarterial ECMO.

DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial of patients (who were eligible if they had been endotracheally intubated and were receiving venoarterial ECMO for cardiogenic shock for <6 hours) conducted in the intensive care units at 20 French cardiac shock care centers between October 2016 and July 2019. Of 786 eligible patients, 374 were randomized. Final follow-up occurred in November 2019.

INTERVENTIONS: Early moderate hypothermia (33-34 °C; n = 168) for 24 hours or strict normothermia (36-37 °C; n = 166).

MAIN OUTCOMES AND MEASURES: The primary outcome was mortality at 30 days. There were 31 secondary outcomes including mortality at days 7, 60, and 180; a composite outcome of death, heart transplant, escalation to left ventricular assist device implantation, or stroke at days 30, 60, and 180; and days without requiring a ventilator or kidney replacement therapy at days 30, 60, and 180. Adverse events included rates of severe bleeding, sepsis, and number of units of packed red blood cells transfused during venoarterial ECMO.

RESULTS: Among the 374 patients who were randomized, 334 completed the trial (mean age, 58 [SD, 12] years; 24% women) and were included in the primary analysis. At 30 days, 71 patients (42%) in the moderate hypothermia group had died vs 84 patients (51%) in the normothermia group (adjusted odds ratio, 0.71 [95% CI, 0.45 to 1.13], P = .15; risk difference, -8.3% [95% CI, -16.3% to -0.3%]). For the composite outcome of death, heart transplant, escalation to left ventricular assist device implantation, or stroke at day 30, the adjusted odds ratio was 0.61 (95% CI, 0.39 to 0.96; P = .03) for the moderate hypothermia group compared with the normothermia group and the risk difference was -11.5% (95% CI, -23.2% to 0.2%). Of the 31 secondary outcomes, 30 were inconclusive. The incidence of moderate or severe bleeding was 41% in the moderate hypothermia group vs 42% in the normothermia group. The incidence of infections was 52% in both groups. The incidence of bacteremia was 20% in the moderate hypothermia group vs 30% in the normothermia group.

CONCLUSIONS AND RELEVANCE: In this randomized clinical trial involving patients with refractory cardiogenic shock treated with venoarterial ECMO, early application of moderate hypothermia for 24 hours did not significantly increase survival compared with normothermia. However, because the 95% CI was wide and included a potentially important effect size, these findings should be considered inconclusive.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02754193.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Levy B, Girerd N, Amour J, et al. Effect of Moderate Hypothermia vs Normothermia on 30-Day Mortality in Patients With Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation: A Randomized Clinical Trial. JAMA. 2022. PMID: 35103766. doi:10.1001/jama.2021.24776

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。